UK JIA Biologics Register

2024: A YEAR IN REVIEW

For study participants and their families

35

NHS sites have provided data in 2024

67

Participants recruited in 2024

3,703

Total participants recruited since the studies began

4 RESEARCH ARTICLES PUBLISHED USING UK JIA BIOLOGICS REGISTER DATA

Please follow the QR code to read the full article

Treated with methotrexate? Machine learning finds subgroups of people who do well

Switching from originator to biosimilar anti-TNF? Children do just as well as those remaining on the originator.

Genetic risk factors (alongside clinical factors) found to help, identification of uveitis in patients with JIA

First anti-TNF not working? Children with polyarticular JIA do just as well on a second anti-TNF as those switching to a non-TNF biologic

Looking to 2025:

- **Recruitment of new participants continues** (including people with JIA who start treatment with biologic, biosimilar or JAKi therapy).
- **Follow-up data collection** continues via your hospital.
- Participants who have reached **16 years of age (or above) should be approached to be re-consented** by the team at the hospital, as they are now old enough to consent for themselves.
- Work on **linking information with NHS England** has started, with Research Fellow Dr Lianne Kearsley-Fleet looking at looking at what happens to those diagnosed with JIA as they progress into adulthood.

HTTPS://SITES.MANCHESTER.AC.UK/BCRDBSPAR/FOR-PARTICIPANTS/

ANY QUESTIONS? PLEASE CONTACT KATY.MOWBRAY@MANCHESTER.AC.UK